Physician profile
David Stansfield
NPI 1619963253
$8,798.54
in general payments reported to CMS, 2019-2025
45 companies · $539 in 2025
The $539 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $857 · 2021: $1,456 · 2022: $2,149 · 2023: $1,612 · 2024: $1,185 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,827.12 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $808.48 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $789.91 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $766.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $462.23 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Allergan, INC. | $417.63 | 2019-2020 | |
| Amgen INC. | $306.64 | 2020-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $300.78 | 2020-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $208.25 | 2019-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.86 | 2019-2024 | Jardiance |
| Pfizer INC. | $144.86 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $136.05 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $135.41 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $128.87 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $97.93 | 2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stansfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.